BENJAMIN M DJULBEGOVIC

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi At what degree of belief in a research hypothesis is a trial in humans justified?
    Benjamin Djulbegovic
    Interdisciplinary Oncology Programme, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    J Eval Clin Pract 8:269-76. 2002
  2. ncbi Screening mammography at 40-49 years: regret or no regret?
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Department of Interdisciplinary Oncology, Tampa, FL 33612, USA
    Lancet 368:2035-7. 2006
  3. pmc Use of re-randomized data in meta-analysis
    Iztok Hozo
    Department of Mathematics, Indiana University Northwest, Gary, IN, USA
    BMC Med Res Methodol 5:17. 2005
  4. pmc Choosing a control intervention for a randomised clinical trial
    Howard Mann
    Department of Radiology, 1A71 University Hospital, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    BMC Med Res Methodol 3:7. 2003
  5. pmc Estimating the mean and variance from the median, range, and the size of a sample
    Stela Pudar Hozo
    Department of Mathematics, Indiana University Northwest, Gary, IN 46408, USA
    BMC Med Res Methodol 5:13. 2005
  6. pmc Quality and methods of developing practice guidelines
    Hugh Cruse
    H Lee Moffitt Cancer Center and Research Institute, The University of South Florida, Tampa, FL, USA
    BMC Health Serv Res 2:1. 2002
  7. pmc Erythropoietin, uncertainty principle and cancer related anaemia
    Otavio Clark
    Interdisciplinary Oncology Program H, Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL, USA
    BMC Cancer 2:23. 2002
  8. ncbi The uncertainty principle and industry-sponsored research
    B Djulbegovic
    Division of Blood and Bone Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    Lancet 356:635-8. 2000
  9. ncbi Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Best Pract Res Clin Haematol 18:455-66. 2005
  10. ncbi What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Treat Rev 32:572-6. 2006

Research Grants

  1. Equipoise and the research integrity of clinical trials
    Benjamin Djulbegovic; Fiscal Year: 2003
  2. Evaluation of the Quality of Clinical Trials
    Benjamin Djulbegovic; Fiscal Year: 2006
  3. Quality of Research on Treatment Harms in Cancer
    Benjamin Djulbegovic; Fiscal Year: 2007

Collaborators

Detail Information

Publications39

  1. ncbi At what degree of belief in a research hypothesis is a trial in humans justified?
    Benjamin Djulbegovic
    Interdisciplinary Oncology Programme, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    J Eval Clin Pract 8:269-76. 2002
    ..The purpose of this study is to determine the degree of uncertainty in a research hypothesis before it can empirically be tested in an RCT...
  2. ncbi Screening mammography at 40-49 years: regret or no regret?
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Department of Interdisciplinary Oncology, Tampa, FL 33612, USA
    Lancet 368:2035-7. 2006
  3. pmc Use of re-randomized data in meta-analysis
    Iztok Hozo
    Department of Mathematics, Indiana University Northwest, Gary, IN, USA
    BMC Med Res Methodol 5:17. 2005
    ..The probability of an event is not always the same when a patient is re-randomized; there is probably a non-zero covariance coming from observations on the same patient. This is of particular importance to the meta-analysts...
  4. pmc Choosing a control intervention for a randomised clinical trial
    Howard Mann
    Department of Radiology, 1A71 University Hospital, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    BMC Med Res Methodol 3:7. 2003
    ..The ethical recruitment of patients requires the presence of clinical equipoise. This involves the appropriate choice of a control intervention, particularly when unapproved drugs or innovative interventions are being evaluated...
  5. pmc Estimating the mean and variance from the median, range, and the size of a sample
    Stela Pudar Hozo
    Department of Mathematics, Indiana University Northwest, Gary, IN 46408, USA
    BMC Med Res Methodol 5:13. 2005
    ..However, sometimes the published reports of clinical trials only report the median, range and the size of the trial...
  6. pmc Quality and methods of developing practice guidelines
    Hugh Cruse
    H Lee Moffitt Cancer Center and Research Institute, The University of South Florida, Tampa, FL, USA
    BMC Health Serv Res 2:1. 2002
    ..It is not known whether there are differences in the quality and recommendations between evidence-based (EB) and consensus-based (CB) guidelines. We used breast cancer guidelines as a case study to assess for these differences...
  7. pmc Erythropoietin, uncertainty principle and cancer related anaemia
    Otavio Clark
    Interdisciplinary Oncology Program H, Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL, USA
    BMC Cancer 2:23. 2002
    ..We also wanted to demonstrate that cumulative meta-analysis (CMA) can be used to resolve uncertainty regarding clinical questions...
  8. ncbi The uncertainty principle and industry-sponsored research
    B Djulbegovic
    Division of Blood and Bone Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    Lancet 356:635-8. 2000
    ..Studies in which intervention and control are thought to be non-equivalent violates the uncertainty principle...
  9. ncbi Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Best Pract Res Clin Haematol 18:455-66. 2005
    ..In this paper, the findings from the guidelines set by ASH/ASCO that were culled from systematic reviews by BCBSA TEC and the Cochrane Review are compared and contrasted...
  10. ncbi What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Treat Rev 32:572-6. 2006
  11. ncbi Articulating and responding to uncertainties in clinical research
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, University of South Florida, Tampa, Florida 33612, USA
    J Med Philos 32:79-98. 2007
    ..That is, [acknowledgement of] uncertainty determines a pattern of success in medicine and drives clinical discoveries...
  12. ncbi The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Account Res 10:301-15. 2003
    ..We argue that an adequate control intervention can be selected if people designing a trial explicitly take into consideration the ethical principle of equipoise, also known as "the uncertainty principle."..
  13. ncbi Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research
    B Djulbegovic
    Interdisciplinary Oncology Program, Division of Blood and Bone Marrow Transplantation, H Lee Moffitt Cancer Center, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Curr Oncol Rep 3:389-95. 2001
    ..We postulate that about 50% of innovations are successful, leading to the conclusion that preserving the ethics of clinical research may be the best investment strategy available...
  14. ncbi Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review
    Benjamin Djulbegovic
    Malignant Hematology Program, H Lee Moffitt Cancer Center Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Control 10:17-41. 2003
    ..They hypothesize that NM-allo-SCT is equally efficacious to standard allo-SCT but produces less regimen-related toxicity...
  15. ncbi Management of multiple myeloma: a systematic review and critical appraisal of published studies
    Ambuj Kumar
    Interdisciplinary Oncology Program of the H Lee Moffitt Cancer and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Lancet Oncol 4:293-304. 2003
    ..We conclude that the quality of total evidence supporting treatment recommendations in myeloma is modest at best and has an ample scope for improvement...
  16. ncbi A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer
    Tawee Tanvetyanon
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    J Thorac Oncol 2:1091-7. 2007
    ..We evaluated available literatures to summarize the state of current knowledge and provide suggestions for future studies...
  17. ncbi Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?
    Mohamed A Kharfan-Dabaja
    Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Rsearch Institute, University of South Florida, Tampa, FL 33612, USA
    Br J Haematol 139:234-42. 2007
    ..It is uncertain whether autograft is superior to conventional therapy. The high incidence of myelodysplastic syndrome (9-12%) is particularly concerning in CLL, where median survival is 9 years...
  18. ncbi Epistemologic inquiries in evidence-based medicine
    Benjamin Djulbegovic
    Center for Evidence Based Medicine and Health Outcomes Research and the Clinical Translational Science Institute at the University of South Florida, Tampa, Florida 33612, USA
    Cancer Control 16:158-68. 2009
    ..Undertaking epistemological inquiry is important because the adoption of a particular epistemological view defines how science is conducted...
  19. pmc Impact of quality of evidence on the strength of recommendations: an empirical study
    Benjamin Djulbegovic
    Center for Evidence based Medicine and Health Outcome Research, Clinical Translational Science Institute, Florida, USA
    BMC Health Serv Res 9:120. 2009
    ..Surprisingly, and despite the widespread penetration of EBM in health care, there has been no empirical research to date investigating the impact of quality of evidence on the strength of recommendations made by guidelines panels...
  20. pmc The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research
    Benjamin Djulbegovic
    Center for Evidence Based Medicine and Health Outcomes Research and the Clinical Translational Science Institute, The University of South Florida, Tampa, Florida 33612, USA
    Cancer Control 16:342-7. 2009
    ..This guarantee is provided by the acknowledgment of uncertainty (equipoise), which removes ethical dilemmas and makes it easier for patients to enroll in clinical trials...
  21. ncbi Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations
    Benjamin Djulbegovic
    Medicine and Oncology, University of South Florida, Tampa, FL 33612, USA
    J Support Oncol 8:84-91. 2010
    ..Hence, there is an urgent need to develop a clinical decision-support system that can help integrate benefits and risks as well as take into account patients' preferences and values in managing VTE...
  22. doi Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review
    Ambuj Kumar
    Center for Evidence based Medicine and Health Outcome Research, University of South Florida
    Am J Hematol 86:18-24. 2011
    ..53, 95% CI 0.38-0.73) favoring MPB. There is an uncertainty about definitive superiority of one type of regimen over the other. Therefore, direct head-to-head comparison between these competing regimens is warranted...
  23. pmc The Australian 'FORM' approach to guideline development: the quest for the perfect system
    Philipp Dahm
    Department of Urology and Prostate Disease Center, University of Florida, College of Medicine, Gainesville, FL, USA
    BMC Med Res Methodol 11:17. 2011
    ..The Australian National Health and Medical Research Council has developed and pilot-tested a new framework for guideline development, the FORM approach, the role of which has yet to be further defined...
  24. ncbi A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    Cancer Control 10:306-14. 2003
    ..Computed tomography (CT) screening of the chest has shown promise for early detection of lung cancer, but evidence for a reduction in lung cancer mortality by CT screening is not available...
  25. ncbi Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence
    Ambuj Kumar
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Department of Interdisciplinary Oncology and Cancer Prevention and Control, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Treat Rev 32:577-80. 2006
  26. ncbi Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design
    Madhusmita Behera
    Malignant Hematology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Control 14:160-6. 2007
    ..The randomized, controlled trial (RCT) is the "gold standard" for establishing the effect of any intervention. This approach, however, is often not feasible with rare diseases such as cutaneous T-cell lymphoma...
  27. pmc Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group
    Ambuj Kumar
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    BMJ 331:1295. 2005
    ....
  28. doi Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis
    Ambuj Kumar
    Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
    J Natl Cancer Inst 101:100-6. 2009
    ..We performed a systematic review and meta-analysis to synthesize the existing evidence related to the effectiveness of tandem vs single AHCT in patients with MM...
  29. pmc Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group
    Heloisa P Soares
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    BMJ 328:22-4. 2004
    ..To determine whether poor reporting of methods in randomised controlled trials reflects on poor methods...
  30. ncbi Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches. Journal of Evaluation in Clinical Practice 12, 248-256
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Department of Interdisciplinary Oncology, Tampa, FL, USA
    J Eval Clin Pract 12:257-9. 2006
  31. ncbi Why evidence based oncology management
    Ambuj Kumar
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    J Oncol Manag 11:13-6. 2002
  32. pmc When should potentially false research findings be considered acceptable?
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, United States of America
    PLoS Med 4:e26. 2007
    ..Obtaining absolute "truth" in research is impossible, and so society has to decide when less-than-perfect results may become acceptable...
  33. doi Multiple myeloma: detecting the effects of new treatments
    Benjamin Djulbegovic
    Division of Hematologic Malignancies, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Lancet 371:1642-4. 2008
  34. doi Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review
    Rahul Mhaskar
    Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 15:893-902. 2009
    ..But the quality of our evidence is low, indicating a need for well-designed and adequately powered RCTs to better address the role of AHCT in AL amyloidosis...
  35. doi Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9416, USA
    Biol Blood Marrow Transplant 15:1415-21. 2009
    ..PBSC is the optimal stem cell source in terms of both overall and quality-adjusted life expectancy, except in conditions with a very low relapse probability, in which BM provides optimal outcomes...
  36. pmc Evaluation of new treatments in radiation oncology: are they better than standard treatments?
    Heloisa P Soares
    H Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa 33612, USA
    JAMA 293:970-8. 2005
    ..To describe accurately the outcomes of innovations that are tested in randomized controlled trials (RCTs) 3 factors have to be considered: publication rate, quality of trials, and the choice of the adequate comparator intervention...
  37. ncbi Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups
    Ambuj Kumar
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL 33612, USA
    J Clin Oncol 25:1272-6. 2007
    ..A systematic review to assess the accurate participation of elderly patients in RCTs has not been performed...
  38. pmc Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center, 12902 Magnolia Dr, MRC, Room 2067H, Tampa, FL 33612, USA
    Arch Intern Med 168:632-42. 2008
    ..We assessed how often experimental cancer treatments that undergo testing in randomized clinical trials (RCTs) result in discovery of successful new interventions...
  39. ncbi Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
    Melissa Alsina
    Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute and Department of Oncology, University of South Florida, Tampa, FL 33612, USA
    Blood 103:3271-7. 2004
    ..We conclude that tipifarnib is tolerable, can induce disease stabilization, and can inhibit farnesylation and oncogenic/tumor survival pathways...

Research Grants3

  1. Equipoise and the research integrity of clinical trials
    Benjamin Djulbegovic; Fiscal Year: 2003
    ..This proposal will answer both the question "what do trials do for us?" and assess the reliability of the research in which public has invested so much. ..
  2. Evaluation of the Quality of Clinical Trials
    Benjamin Djulbegovic; Fiscal Year: 2006
    ..It is also hoped that public confidence in COG research may further increase, which in turn will enable development of more rapid advances in the war against cancer. ..
  3. Quality of Research on Treatment Harms in Cancer
    Benjamin Djulbegovic; Fiscal Year: 2007
    ..Finally, the improvement of the reporting of harms would benefit physicians and above all patients, who need to understand the potential harms of the treatments they receive. ..